Terms: = Germ cell tumor AND PSA AND Diagnosis
46 results:
1. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract] [Full Text] [Related]
2. Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
Egger S; Smith DP; Patel MI; Kimlin MG; Armstrong BK; Nair-Shalliker V
Br J Cancer; 2023 Jan; 128(1):71-79. PubMed ID: 36319848
[TBL] [Abstract] [Full Text] [Related]
3. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
[TBL] [Abstract] [Full Text] [Related]
5. [diagnosis and treatment of small cell neuroendocrine carcinoma of the prostate].
Zhang M; Shi W; Zhang QW; Wang W; Li QY
Zhonghua Nan Ke Xue; 2021 Mar; 27(3):219-225. PubMed ID: 34914303
[TBL] [Abstract] [Full Text] [Related]
6. Somatic-Type Yolk Sac tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract] [Full Text] [Related]
7. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
Bell PD; Huber AR; Agostini-Vulaj D
Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
[TBL] [Abstract] [Full Text] [Related]
9. Prostate cancer testicular metastasis: Are they underestimated? Case report and analysis of the literature.
Smelzo S; Mantica G; Lucianò R; Tenace NP; De Marchi D; Pini G; Passaretti G; Losa A; Gaboardi F
Urologia; 2022 Nov; 89(4):645-647. PubMed ID: 33832367
[TBL] [Abstract] [Full Text] [Related]
10. [Pathological features of primary extragonadal germ cell tumor of the prostate with small round blue cell morphology].
Gan HL; Wang QF
Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):108-113. PubMed ID: 33535304
[No Abstract] [Full Text] [Related]
11. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
12. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.
Williams SG; Aw Yeang HX; Mitchell C; Caramia F; Byrne DJ; Fox SB; Haupt S; Schittenhelm RB; Neeson PJ; Haupt Y; Keam SP
BMC Urol; 2020 Oct; 20(1):171. PubMed ID: 33115461
[TBL] [Abstract] [Full Text] [Related]
13. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract] [Full Text] [Related]
14. Neuroendocrine Cancer of the Prostate.
Kránitz N; Szepesváry Z; Kocsis K; Kullmann T
Pathol Oncol Res; 2020 Jul; 26(3):1447-1450. PubMed ID: 31414399
[TBL] [Abstract] [Full Text] [Related]
15. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract] [Full Text] [Related]
16. diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract] [Full Text] [Related]
17. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract] [Full Text] [Related]
18. [Clinical characteristics of 13 neuroendocrine prostate cancer patients].
Zhang WH; Si TG; Yang XL; Yang B; Liu CF; Yu HP; Xing WG; Guo Z
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1316-1319. PubMed ID: 28482433
[No Abstract] [Full Text] [Related]
19. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.
Soliman ML; Tiwari A; Zhao Q
World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485
[TBL] [Abstract] [Full Text] [Related]
20. Radiopharmaceuticals for the diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract] [Full Text] [Related]
[Next]
